Alnylam to Webcast Virtual R&D Day

Rhea-AI Summary

Alnylam Pharmaceuticals, Inc. (ALNY) to Webcast Virtual R&D Day Event on December 13, 2023

Positive

• Alnylam Pharmaceuticals, Inc. (ALNY) is holding a virtual R&D Day event on December 13, 2023 at 8:30 am ET.
• The event will be webcast on the Investors section of the company's website, with a replay available within 48 hours after the event.

Negative

• None.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming virtual R&D Day event on the Investors section of the Company’s website, www.alnylam.com, on Wednesday, December 13, 2023 at 8:30 am ET. A replay will be available on the Alnylam website within 48 hours after the event.

About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO^® (patisiran), AMVUTTRA^® (vutrisiran), GIVLAARI^® (givosiran), OXLUMO^® (lumasiran), and Leqvio^® (inclisiran), which is being developed and commercialized by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P⁵x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on X (formerly Twitter) at @Alnylam, or on LinkedIn, Facebook, or Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231205922348/en/

Alnylam Pharmaceuticals, Inc.

Christine Regan Lindenboom

(Investors and Media)

+1-617-682-4340

Josh Brodsky

(Investors)

+1-617-551-8276

Source: Alnylam Pharmaceuticals, Inc.

FAQ

What is the date of Alnylam Pharmaceuticals, Inc.'s virtual R&D Day event?

The virtual R&D Day event is scheduled for December 13, 2023.

Where can I watch the webcast of Alnylam Pharmaceuticals, Inc.'s R&D Day event?

The webcast will be available on the Investors section of the company's website, www.alnylam.com.

When will the replay of the event be available?

The replay will be available within 48 hours after the event on the Alnylam website.